Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC
By Jea-Woon Ryu, Seon-Kyu Kim, M. Son, S. Jeon, Jung-Hwa Oh, J. Lim, Sunwha Cho, Cho-Rok Jung, Ryuji Hamamoto, Dae-Soo Kim and 1 more. 2017
31 citations recorded by the source corpus.
Hepatocellular carcinoma (HCC) is a major type of liver cancer caused by the hepatitis B and C viruses, alcohol and exposure to aflatoxin. For HCC treatment, anticancer drugs have been widely used, but drug resistance in advanced HCC is an important problem, resulting in a continuous need for novel therapeutic targets. Therefore, in this study, we established a screening pipeline based on RNA-seq to screen novel therapeutic/prognostic targets in HCC and identified PRMT1 (Protein Arginine Methyltransferase 1). In the prognostic analysis, the overexpression of PRMT1 was clearly associated with poor prognosis in a number of HCC patient cohorts. Moreover, after PRMT1 knockdown, HCC cell lines exhibited cell growth and spheroid formation suppression, an increase in Sub-G1 cells by FACS analysis, and enrichment of the cell cycle pathway via functional enrichment analysis. With these results, we demonstrated that PRMT1 could be a novel prognostic marker and therapeutic target for HCC therapy.
Subfields: Molecular Biology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Ryuji Hamamoto
- Hyun-soo Cho
- Yusuke Nakamura
- N. Dohmae
- Takehiro Suzuki
- Makoto Nakakido
- Lianhua Piao
- G. Toyokawa
Citations in the corpus
- The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer (2018, methodology): “Following EHMT2 knockdown, 1x104 cells were loaded onto a spheroid culture plate, grown for 3 days, and then observed under a microscope(Ti‐S; Nikon, Tokyo, Japan), as previously described (22).”